Kolelang

Colistimethate sodium, the active ingredient in Kolelang, is a polymyxin antibiotic presented as a sterile injectable solution for intracerebroventricular and intrathecal use. It treats severe infections caused by susceptible Gram‑negative bacteria, particularly in the central nervous system.

GNH USA supplies Kolelang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Kolelang is a polymyxin antibiotic used for serious Gram‑negative bacterial infections affecting the central nervous system.

- Gram‑negative bacterial meningitis: provides bactericidal activity to eradicate the infection within the cerebrospinal fluid. - Post‑neurosurgical CNS infection: helps control resistant Gram‑negative pathogens after surgical procedures. - Ventriculitis caused by susceptible organisms: delivers high local concentrations to clear infection in the ventricular system.

Colistimethate sodium may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate pain in the head region. - Nausea: feeling of sickness often accompanied by an urge to vomit. - Fever: elevated body temperature during treatment. - Dizziness: sensation of light‑headedness or unsteadiness. - Injection‑site pain: local discomfort at the administration site. - Tingling or paresthesia: transient sensory disturbances.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Anaphylaxis: severe allergic reaction with airway compromise. - Nephrotoxicity: acute kidney injury manifested by rising creatinine. - Severe neurotoxicity: profound peripheral neuropathy or encephalopathy. - Respiratory paralysis: loss of breathing effort, potentially life‑threatening. - Hypersensitivity reactions: rash, urticaria, or angioedema.

When using Kolelang, several precautions should be observed to minimize risks.

- Renal function monitoring: assess serum creatinine before and during therapy. - Neurological assessment: watch for signs of neurotoxicity. - Dosage adjustment in renal impairment: reduce dose as recommended. - Avoid concurrent nephrotoxic agents: limit exposure to other kidney‑toxic drugs. - Pregnancy and lactation: use only if benefit outweighs risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Colistimethate sodium can interact with other medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Aminoglycosides: additive nephrotoxicity and neurotoxicity. - Loop diuretics: increased risk of kidney injury. - Neuromuscular blocking agents: potentiation of respiratory paralysis.

Moderate Interactions (Monitor Closely): - Vancomycin: possible additive nephrotoxicity. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may worsen renal function.